0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
JAMA Oncology Clinical Challenge  | 
Melanoma and a Headache
Douglas B. Johnson, MD, MSCI; Tejaswi V. Mudigonda, BS; Jeffrey A. Sosman, MD
JAMA Dermatology
Original Investigation  | 
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, MD; Igor Vujic, MD; Adil Daud, MD; et al.
JAMA Oncology
Invited Commentary  | 
Chemotherapy Near the End of Life First—and Third and Fourth (Line)—Do No Harm
Charles D. Blanke, MD; Erik K. Fromme, MD
JAMA Oncology
Invited Commentary  | 
Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence—Not Accurate Enough?  More Education May Be Needed
Heikki Joensuu, MD